AI Article Synopsis
- BPA is an endocrine disruptor that activates specific receptors, increasing drug-metabolizing enzymes in human liver cells (Hep3B).
- BPA exposure raised nitric oxide (NO) levels without increasing reactive oxygen species (ROS), and led to the activation of Nrf2 through the inactivation of its regulator, Keap1.
- This study suggests that BPA’s elevation of NO levels plays a crucial role in the induction of Nrf2-dependent drug-metabolizing enzymes and highlights a potential mechanism for its effects on drug metabolism.
Article Abstract
Bisphenol A (BPA) is an endocrine-disrupting chemical, and activates the aryl hydrocarbon receptor (AhR) and the estrogen receptor, leading to the induction of drug metabolizing enzymes. In this study, we found that BPA increased nitric oxide (NO) levels but not reactive oxygen species (ROS) levels in the human hepatoma cell line, Hep3B, and induced drug-metabolizing enzymes such as UDP-glucuronosyltransferase (UGT). Nuclear factor erythroid 2-related factor 2 (Nrf2) has been reported to be activated by ROS through inactivation of its regulating protein, Kelch-like ECH-associated protein (Keap1), and to be the key mediator of phase I and phase II drug metabolizing enzymes, and phase III drug transporters. Treatment of Hep3B with BPA increased the levels of nitrous oxide, a metabolite of nitric oxide and activated Nrf2 by nitrosylation of Keap1, leading to the induction of heme oxygenase-1 (HO-1) and UGT2B1 mRNAs. A nitric oxide donor, 1-Hydroxy-2-oxo-3-(N-methyl-3-aminopropyl)-3-methyl-1-triazene (NOC7), also activated Nrf2 and a NOS inhibitor, N-Monomethyl-l-arginine, monoacetate salt (L-NMMA), inhibited activation of Nrf2 by BPA. Furthermore, calcium efflux by BPA was observed. These results suggested the new idea that BPA increases NO levels and activates Nrf2 via Keap1 inactivation, leading to induction of Nrf2-dependent drug-metabolizing enzymes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dmpk.2018.04.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Physiologically Based Pharmacokinetic Model of Cefotaxime in Patients with Impaired Renal Function.
Clin Pharmacokinet
January 2025
Inria-Inserm COMPO Team, Centre Inria Sophia Antipolis-Méditerranée, CRCM, Inserm U1068-CNRS UMR7258-Aix-Marseille University UM105, Marseille, France.
Background: Cefotaxime is a widely prescribed cephalosporin antibiotic used to treat various infections. It is mainly eliminated unchanged by the kidney through tubular secretion and glomerular filtration. Therefore, a reduction of kidney function may increase exposure to the drug and induce toxic side effects.
View Article and Find Full Text PDFPositioning Enzyme- and Transporter-Based Precipitant Drug-Drug Interaction Studies in Drug Design.
J Med Chem
January 2025
Department of Pharmacokinetics Dynamics & Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States.
assessment of the potential of compounds to affect drug metabolizing enzymes and transporters and perpetrate drug-drug interactions (DDIs) is a common practice in drug research. For the development phase, regulators define an exhaustive list of enzymes and transporters to consider, but DDIs associated with many of these are minor and can be well-managed in the clinic; thus, progression of drug candidates that address unmet medical needs should not be curtailed due to this property. However, some enzymes and transporters are very important in drug disposition, so it is important to avoid/reduce inhibition or induction of these through drug design.
View Article and Find Full Text PDFUnraveling Caco-2 Cells through Functional and Transcriptomic Assessments.
Regul Toxicol Pharmacol
January 2025
Division of Applied Regulatory Science, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, The U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, United States of America. Electronic address:
The static Caco-2 monolayer is an extensively utilized model for predicting the permeability of small molecules during the drug development process. While these cells can differentiate and develop key functional and morphological features that emulate human enterocytes, they do not fully replicate the complexity of human intestinal physiology. In this study, we investigated functional and morphological aspects of Caco-2 cells, alongside their transcriptomic profiles, with a particular emphasis on genes encoding drug-metabolizing enzymes and drug transporters.
View Article and Find Full Text PDF[Precision Medicine for Patients with Renal Cell Carcinoma Based on Drug-metabolizing Enzyme Expression Levels].
Yakugaku Zasshi
January 2025
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.
Notable advances have recently been achieved in drug therapies for renal cell carcinoma (RCC). Several tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have been approved for metastatic RCC (mRCC). The current first-line treatment for mRCC involves combination therapies using TKIs and ICIs.
View Article and Find Full Text PDFGreen Tea Catechins as Perpetrators of Drug Pharmacokinetic Interactions.
Clin Pharmacol Ther
January 2025
Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Green tea (Camellia sinensis) is a commonly consumed beverage or dietary supplement. As a natural product with a myriad of proposed health benefits, patients are likely to consume green tea while taking their medications unaware of its potential to interact with drugs and influence drug efficacy and safety. Catechins are the abundant polyphenolic compounds in green tea (e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!